CM4620 to lessen pancreatitis after asparaginase
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests CM4620 to reduce how severe pancreatitis becomes in children and young people with leukemia/lymphoma who develop pancreatitis after receiving a drug called asparaginase. It aims to improve outcomes by calming the inflammation of the pancreas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age under 22 and being treated for leukemia/lymphoma with the goal of cure
- Have acute pancreatitis, confirmed by blood tests (amylase or lipase) and/or symptoms/imaging
- Have taken any form of asparaginase within the last 49 days
- Do not have had pancreatitis before (no prior pancreatitis history)
- Baseline heart rhythm test (QTc) must not be too prolonged (not >450 ms)
- Cannot be pregnant or breastfeeding, and must use effective birth control if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the side effects of the drug asparaginase in children and young adults with certain types of leukemia or lymphoma. It aims to better understand and manage these side effects to improve treatment safety.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
This study looks at how the immune system reacts to a chemotherapy drug called PEG asparaginase in children and young adults. Understanding this could help improve treatment for leukemia by managing or reducing allergic reactions.
This trial tests if taking aspirin daily can prevent repeated attacks of acute pancreatitis. It's for people who have had at least two episodes of pancreatitis in the past year that were not caused by a medical procedure.
This trial tests a light-activated drug called ASP-1929 for people with locally advanced pancreatic cancer who have completed chemotherapy before surgery. The drug targets cancer cells and is activated by a special light during surgery.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.